Pro Phase Labs, Inc. PRPH
We take great care to ensure that the data presented and summarized in this overview for ProPhase Labs, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PRPH
View all-
Vanguard Group Inc Valley Forge, PA656KShares$511,6380.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny215KShares$167,7850.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL179KShares$139,6550.0% of portfolio
-
Geode Capital Management, LLC Boston, MA161KShares$125,3730.0% of portfolio
-
Perritt Capital Management Inc Chicago, IL82.9KShares$64,6860.11% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA64.9KShares$50,6260.0% of portfolio
-
Black Rock Inc. New York, NY64.3KShares$50,1530.0% of portfolio
-
Chapin Davis, Inc. Baltimore, MD50KShares$39,0000.04% of portfolio
-
State Street Corp Boston, MA44.7KShares$34,8370.0% of portfolio
-
Northern Trust Corp Chicago, IL41.5KShares$32,3730.0% of portfolio
Latest Institutional Activity in PRPH
Top Purchases
Top Sells
About PRPH
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Insider Transactions at PRPH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 05
2023
|
Ted William Karkus CEO & CHAIRMAN |
BUY
Bona fide gift
|
Indirect |
50,000
+25.0%
|
-
|
|
Apr 05
2023
|
Ted William Karkus CEO & CHAIRMAN |
SELL
Bona fide gift
|
Direct |
50,000
-1.44%
|
-
|
|
Apr 03
2023
|
Ted William Karkus CEO & CHAIRMAN |
SELL
Bona fide gift
|
Direct |
100,000
-2.79%
|
-
|
|
Feb 01
2023
|
Ted William Karkus CEO & CHAIRMAN |
SELL
Payment of exercise price or tax liability
|
Direct |
268,337
-6.97%
|
$2,146,696
$8.18 P/Share
|
|
Feb 01
2023
|
Ted William Karkus CEO & CHAIRMAN |
BUY
Exercise of conversion of derivative security
|
Direct |
500,000
+11.49%
|
$0
$0.6 P/Share
|
|
Jan 13
2023
|
Ted William Karkus CEO & CHAIRMAN |
SELL
Payment of exercise price or tax liability
|
Direct |
319,231
-8.7%
|
$2,873,079
$9.36 P/Share
|
|
Jan 13
2023
|
Ted William Karkus CEO & CHAIRMAN |
BUY
Exercise of conversion of derivative security
|
Direct |
600,000
+14.05%
|
$0
$0.6 P/Share
|
|
Oct 16
2022
|
Ted William Karkus CEO & CHAIRMAN |
SELL
Payment of exercise price or tax liability
|
Direct |
317,291
-9.36%
|
$3,172,910
$10.41 P/Share
|
|
Oct 16
2022
|
Ted William Karkus CEO & CHAIRMAN |
BUY
Exercise of conversion of derivative security
|
Direct |
600,000
+15.04%
|
$0
$0.6 P/Share
|
|
Aug 10
2022
|
Ted William Karkus CEO & CHAIRMAN |
SELL
Payment of exercise price or tax liability
|
Direct |
316,605
-10.2%
|
$3,166,050
$10.84 P/Share
|
|
Aug 10
2022
|
Ted William Karkus CEO & CHAIRMAN |
BUY
Exercise of conversion of derivative security
|
Direct |
600,000
+16.19%
|
$0
$0.6 P/Share
|
|
May 23
2022
|
Monica L. Brady Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,806
-25.29%
|
$94,448
$8.47 P/Share
|
|
May 23
2022
|
Monica L. Brady Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,250
+33.46%
|
$78,500
$2.67 P/Share
|
|
May 23
2022
|
Ted William Karkus CEO & CHAIRMAN |
SELL
Payment of exercise price or tax liability
|
Direct |
278,257
-10.0%
|
$2,226,056
$8.47 P/Share
|
|
May 23
2022
|
Ted William Karkus CEO & CHAIRMAN |
BUY
Exercise of conversion of derivative security
|
Direct |
450,000
+13.92%
|
$900,000
$2.0 P/Share
|
|
Mar 10
2022
|
Jason Michael Barr Director |
BUY
Open market or private purchase
|
Direct |
750
+2.36%
|
$4,500
$6.48 P/Share
|
|
Jun 03
2021
|
Ted William Karkus CEO & CHAIRMAN |
BUY
Open market or private purchase
|
Direct |
33,943
+1.43%
|
$169,715
$5.07 P/Share
|
|
May 07
2021
|
Ted William Karkus CEO & CHAIRMAN |
BUY
Bona fide gift
|
Indirect |
60,000
+37.5%
|
-
|
|
May 07
2021
|
Ted William Karkus CEO & CHAIRMAN |
SELL
Bona fide gift
|
Direct |
120,000
-4.96%
|
-
|